Results 241 to 250 of about 98,414 (282)

Time to accelerate rare disease research: AI‐powered in silico trials, digital twin‐driven RCTs and decision‐grade real‐world evidence

British Journal of Clinical Pharmacology, EarlyView.
Andrej Belančić, Elvira Meni Maria Gkrinia, Oscar Della Pasqua, Reecha Sofat, Dinko Vitezić, Robert Likić   +5 more
wiley   +1 more source

AI and innovation in clinical trials. [PDF]

NPJ Digit Med
Badani A, de Moraes FY, Vollmuth P, Chung C, Mansouri A.   +4 more
europepmc   +1 more source

Artificial Intelligence Based in silico Clinical Trials for Vaccines

Palak Gupta, Akshita Singh, Debaprasad Mukherjee   +2 more
openaire   +1 more source

New and Emerging Research Models for Sepsis. [PDF]

Cells
Nallajennugari S, Li X, Fu M.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

In Silico Clinical Trials: Is It Possible?

2023
Modeling and simulation (M&S), including in silico (clinical) trials, helps accelerate drug research and development and reduce costs and have coined the term "model-informed drug development (MIDD)." Data-driven, inferential approaches are now becoming increasingly complemented by emerging complex physiologically and knowledge-based disease (and drug)
Simon, Arsène, Yves, Parès, Eliott, Tixier, Solène, Granjeon-Noriot, Bastien, Martin, Lara, Bruezière, Claire, Couty, Eulalie, Courcelles, Riad, Kahoul, Julie, Pitrat, Natacha, Go, Claudio, Monteiro, Julie, Kleine-Schultjann, Sarah, Jemai, Emmanuel, Pham, Jean-Pierre, Boissel, Alexander, Kulesza   +16 more
openaire   +2 more sources

In-silico trial of intracranial flow diverters replicates and expands insights from conventional clinical trials [PDF]

Nature Communications, 2021
Abstract The cost of clinical trials is ever-increasing. In-silico trials rely on virtual populations and interventions simulated using patient-specific models and may offer a solution to lower these costs. We present the flow diverter performance assessment (FD-PASS) in-silico trial, which models the treatment of intracranial ...
Ali Sarrami-Foroushani, Toni Lassila, James V Byrne   +2 more
exaly   +10 more sources